Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 3/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274751 | 1.00 | CPS1 (0.39) | CPS1SPHK2HCRTR2HCRTR1KCNH2 | |
| SCHEMBL12102139 | 1.00 | CPS1 (0.39) | CPS1SPHK2HCRTR2HCRTR1KCNH2 | |
| SCHEMBL3279287 | 0.88 | GRM5 (0.44) | CPS1SPHK2HCRTR2HCRTR1KCNH2 | |
| SCHEMBL3279292 | 0.88 | GRM5 (0.44) | CPS1SPHK2HCRTR2HCRTR1KCNH2 | |
| SCHEMBL12102126 | 0.88 | GRM5 (0.44) | CPS1SPHK2HCRTR2HCRTR1KCNH2 | |
| SCHEMBL3275435 | 0.86 | SPHK2 (0.46) | SPHK2HCRTR1HRH3HTR3ASPHK1 | |
| SCHEMBL3275431 | 0.86 | SPHK2 (0.46) | SPHK2HCRTR1HRH3HTR3ASPHK1 | |
| SCHEMBL12102135 | 0.86 | SPHK2 (0.46) | SPHK2HCRTR1HRH3HTR3ASPHK1 | |
| SCHEMBL12993585 | 0.86 | ALOX5 (0.39) | CPS1HCRTR2HCRTR1KCNH2HRH3 | |
| SCHEMBL3587048 | 0.86 | ALOX5 (0.39) | CPS1HCRTR2HCRTR1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756051-B1 | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI (US) | 2012-09-12 | — | — | EP | claimed |
| US-7696234-B2 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | claimed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | claimed |
| EP-1756051-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005121080-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-22 | — | — | WO | claimed |
| EP-1756051-B1 | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI (US) | 2012-09-12 | — | — | EP | disclosed |
| US-7696234-B2 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | HRH3, HRH4, HCRTR1 | CPS1 1255/4885SPHK2 720/4885HCRTR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.